Novartis announced the results from two pivotal, Phase III studies, in which Cosentyx (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile.
The data were presented as a late-breaking abstract at the 31st European Academy of Dermatology and Venereology (EADV) Congress.
- Read more about Novartis Cosentyx shows improvement in hidradenitis suppurativa in trials
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/novartis-cosentyx-shows-improvement-in-hidradenitis-suppurativa-in-trials
No comments:
Post a Comment